bioAffinity Technologies Raises ~$4M in Stock Offering via WallachBeth

WallachBeth Capital LLC announced it has arranged an approximately $4 million registered direct financing of common stock for bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology firm focused on developing noninvasive healthcare solutions. The offering is paired with a concurrent private placement and priced at-the-market in compliance with Nasdaq listing rules.

WallachBeth Capital, headquartered in Jersey City, N.J., provides capital markets and institutional execution services, and acted as the placement agent for the transaction. Registered direct offerings of this structure allow companies to sell shares directly to institutional investors without the delays associated with traditional public offerings, while the concurrent private placement component typically involves warrants or other securities not registered at the time of sale.

Read more Lear Capital Podcast Hits Apple Top 15 With 40,000 Downloads →

For bioAffinity Technologies, the capital raise represents a potential source of runway funding as the company advances its pipeline of noninvasive diagnostic technologies. Biotechnology firms at this stage frequently rely on at-the-market and registered direct mechanisms to access growth capital efficiently without significantly disrupting share price through a deeply discounted offering.

The transaction underscores continued activity in small-cap biotech financing, where companies listed on Nasdaq seek to leverage market-priced structures to attract institutional participation. At-the-market pricing is governed by Nasdaq rules designed to protect existing shareholders from excessive dilution. The terms of the private placement component, including any warrant coverage, were not fully detailed in the announcement.

Continue reading at All Financial Services & Investing.